ACADIA to Host Conference Call and Webcast on Tuesday, August 5,
2008, at 8:30 a.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—July 29, 2008—ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will report its unaudited financial results for the second quarterended June 30, 2008 on Tuesday, August 5, 2008, before the U.S.financial markets open. ACADIA's management will host a conferencecall and webcast on Tuesday, August 5, 2008, at 8:30 a.m. Eastern Timeto discuss ACADIA's financial results and development programs.
The conference call may be accessed by dialing 866-825-1709 forparticipants in the U.S. or Canada and 617-213-8060 for internationalcallers (reference passcode 62862758). A telephone replay of theconference call may be accessed through August 19, 2008 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 47546867). The conferencecall also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archivedthere until August 19, 2008.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive clinical programs as well as a portfolio of preclinical anddiscovery assets directed at diseases with large unmet medical needs,including Parkinson's disease psychosis, schizophrenia, sleepmaintenance insomnia, chronic pain, and glaucoma. All of the drugcandidates in ACADIA's product pipeline emanate from discoveries madeusing its proprietary drug discovery platform. ACADIA's corporateheadquarters is located in San Diego, California and it maintainsresearch and development operations in both San Diego and Malmo,Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.Lisa Barthelemy, Director, Investor RelationsThomas H. Aasen, Vice President andChief Financial Officer858-558-2871SOURCE: ACADIA Pharmaceuticals Inc.